Résumé
BACKGROUND: Hypertension is a leading cause of death in sub-Saharan Africa, with a high background prevalence in the general population. First-line use of TAF and DTG lead to higher risks of clinical obesity than tenofovir disoproxil fumarate (TDF) or efavirenz (EFV). Clinical obesity increases the risks of hypertension and other non-communicable diseases (NCDs).METHODS: In the NAMSAL trial, 613 PLWH in Cameroon were randomised to TDF/3TC/DTG or TDF/3TC/EFV (EFV low-dose). In the ADVANCE trial, 1053 PLWH in South Africa were randomised to TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV. In both trials, blood pressure was measured at every study visit. Grade 1 hypertension was defined as SBP/DBP >140/90 mmHg. In ADVANCE, all participants developing Grade 1 hypertension were given antihypertensives. In NAMSAL, <1% of participants were given anti-hypertensives, as funding was not available.